These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25163420)

  • 1. Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-β-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model.
    Schwarzenböck SM; Gertz J; Souvatzoglou M; Kurth J; Sachs D; Nawroth R; Treiber U; Schuster T; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Henriksen G; Wester HJ; Krause BJ
    Mol Imaging Biol; 2015 Apr; 17(2):248-56. PubMed ID: 25163420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
    Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
    Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.
    Krause BJ; Souvatzoglou M; Herrmann K; Weber AW; Schuster T; Buck AK; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler SI; Senekowitsch-Schmidtke R; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1861-8. PubMed ID: 20512572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model].
    Schwarzenböck S; Sachs D; Souvatzoglou M; Schuster T; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler S; Schwaiger M; Senekowitsch-Schmidtke R; Krause BJ
    Nuklearmedizin; 2013; 52(4):141-7. PubMed ID: 23396481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
    Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
    J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC).
    Henriksen G; Herz M; Hauser A; Schwaiger M; Wester HJ
    Nucl Med Biol; 2004 Oct; 31(7):851-8. PubMed ID: 15464386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models.
    Zheng QH; Gardner TA; Raikwar S; Kao C; Stone KL; Martinez TD; Mock BH; Fei X; Wang JQ; Hutchins GD
    Bioorg Med Chem; 2004 Jun; 12(11):2887-93. PubMed ID: 15142549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
    DeGrado TR; Coleman RE; Wang S; Baldwin SW; Orr MD; Robertson CN; Polascik TJ; Price DT
    Cancer Res; 2001 Jan; 61(1):110-7. PubMed ID: 11196147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [11C]choline PET/CT impacts treatment decision making in patients with prostate cancer referred for radiotherapy.
    Jereczek-Fossa BA; Rodari M; Bonora M; Fanti P; Fodor C; Pepe G; Lopci E; Zerini D; Vischioni B; Baroni G; Matei DV; De Cobelli O; Chiti A; Orecchia R
    Clin Genitourin Cancer; 2014 Jun; 12(3):155-9. PubMed ID: 24331577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Zechmann CM; Malcher A; Eder M; Eisenhut M; Linhart HG; Holland-Letz T; Hadaschik BA; Giesel FL; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):11-20. PubMed ID: 24072344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
    Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H
    Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
    Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
    J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
    von Eyben FE; Kairemo K
    Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of deuterated 18F- and 11C-labeled choline analogs for cancer detection by positron emission tomography.
    Witney TH; Alam IS; Turton DR; Smith G; Carroll L; Brickute D; Twyman FJ; Nguyen QD; Tomasi G; Awais RO; Aboagye EO
    Clin Cancer Res; 2012 Feb; 18(4):1063-72. PubMed ID: 22235095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Evaluation of
    Piert M; Shao X; Raffel D; Davenport MS; Montgomery J; Kunju LP; Hockley BG; Siddiqui J; Scott PJH; Chinnaiyan AM; Rajendiran T
    J Nucl Med; 2017 Aug; 58(8):1216-1223. PubMed ID: 28302759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates.
    Krause BJ; Souvatzoglou M; Treiber U
    Urol Oncol; 2013 May; 31(4):427-35. PubMed ID: 21388835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
    Schroeder RP; van Weerden WM; Krenning EP; Bangma CH; Berndsen S; Grievink-de Ligt CH; Groen HC; Reneman S; de Blois E; Breeman WA; de Jong M
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging.
    Hara T; Kosaka N; Kishi H
    J Nucl Med; 2002 Feb; 43(2):187-99. PubMed ID: 11850483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.